PFM Health Sciences’s Centessa Pharmaceuticals CNTA Stock Holding History

PFM Health Sciences’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21M	Sell	528,224 -63,377	-11%	-$1.62M	1.91%	13
2025 Q4	$14.8M	Sell	591,601 -74,595	-11%	-$1.89M	1.48%	26
2025 Q3	$16.2M	Buy	666,196 +321,224	+93%	+$5.71M	1.24%	26
2025 Q2	$4.53M	Sell	344,972 -225,574	-40%	-$2.86M	0.39%	43
2025 Q1	$8.2M	Buy	570,546 +198,780	+53%	+$3.25M	0.6%	37
2024 Q4	$6.23M	Buy	371,766 +102,608	+38%	+$1.7M	0.39%	51
2024 Q3	$4.3M	Sell	269,158 -366,485	-58%	-$4.49M	0.24%	54
2024 Q2	$5.74M	Buy	635,643 +320,969	+102%	+$3.04M	0.28%	56
2024 Q1	$3.56M	Buy	+314,674	New	+$2.98M	0.17%	74

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

PFM Health Sciences's CNTA Position: Q1 2026 in Review

PFM Health Sciences reduced its Centessa Pharmaceuticals (CNTA) stake by 11% in Q1 2026, selling an estimated $1.62M and leaving 528,224 shares worth $21M. The position accounts for 1.91% of the portfolio, ranked #13.

PFM Health Sciences first reported a position in CNTA in Q1 2024 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

PFM Health Sciences held 528,224 shares of Centessa Pharmaceuticals worth $21M as of Q1 2026.
PFM Health Sciences sold 63,377 Centessa Pharmaceuticals shares in Q1 2026, an estimated $1.62M.
Centessa Pharmaceuticals made up 1.91% of PFM Health Sciences's portfolio in Q1 2026, its #13 holding.
PFM Health Sciences first reported a position in Centessa Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.